Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Dr Reddy’s Laboratories ( (RDY) ).
On September 3, 2025, Dr. Reddy’s Laboratories received an order from the Joint Commissioner of Customs in Ludhiana, Punjab, imposing a penalty under the Customs Act, 1962, for allegedly availing export incentives irregularly. The penalty amounts to Rs. 3,00,00,000, but the company has assessed that this will not materially impact its financials, operations, or other activities. Dr. Reddy’s is considering filing an appeal against this order.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories exhibits strong financial health and strategic growth initiatives, particularly in biosimilars and environmental leadership. However, challenges in the U.S. generics market and regulatory issues temper the outlook. The technical indicators suggest a neutral trend, and the valuation appears fair.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and manufacturing of generic medications, active pharmaceutical ingredients, and biologics, with a focus on providing affordable and innovative healthcare solutions globally.
Average Trading Volume: 1,411,417
Technical Sentiment Signal: Buy
Current Market Cap: $11.9B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.